公开(公告)号：US20180355322A1

公开(公告)日：2018-12-13

申请号：US16104533

申请日：2018-08-17

申请人： TOPPAN PRINTING CO., LTD. ,  OSAKA UNIVERSITY

发明人： Kei TSUKAMOTO ,  Shinji IRIE ,  Michiya MATSUSAKI

IPC分类号： C12N5/09

CPC分类号： C12N5/0693 ,  C12M3/00 ,  C12N2501/91

摘要： A method of promoting spheroid formation, including: a preparation step of preparing a mixture obtained by mixing a cell sample with a promoter; and a culture step of culturing, inside a spheroid formation-culture vessel, the mixture obtained in the preparation step, in which the promoter is a polymer in which one or more selected from the group consisting of D-glucosamine, D-galactosamine, D-glucuronic acid, L-iduronic acid, and D-galactose are polymerized.

公开(公告)号：US10000740B2

公开(公告)日：2018-06-19

申请号：US15028085

申请日：2014-10-06

申请人： Cambridge Enterprise Limited

发明人： Ludovic Vallier ,  Nicholas Hannan

IPC分类号： C12N5/071 ,  G01N33/50

CPC分类号： C12N5/068 ,  C12N5/0672 ,  C12N5/0678 ,  C12N5/0689 ,  C12N2500/92 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/12 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/40 ,  C12N2501/415 ,  C12N2501/91 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/45 ,  G01N33/5023

摘要： This invention relates to the differentiation of pluripotent cells (PSCs) into foregut stem cells (FSCs) using a definitive endoderm induction medium comprising a TGFfi ligand, fibroblast growth factor (FGF), bone morphogenetic protein (BMP) and a PI3K inhibitor to differentiate the pluripotent cells into definitive endoderm cells and a foregut induction medium comprising a TGFβ ligand to differentiate the definitive endoderm cells into foregut stem cells (FSCs). Methods of differentiation, populations of foregut stem cells, culture media and kits are provided.

公开(公告)号：US20180087033A1

公开(公告)日：2018-03-29

申请号：US15705896

申请日：2017-09-15

申请人： REGENERATIVE MEDICAL SOLUTIONS, INC.

发明人： Xiaofang Xu ,  Jon Odorico ,  Erik Forsberg ,  Amber A. Mael

IPC分类号： C12N5/071 ,  A61K9/16 ,  A61K9/50 ,  A61K35/39 ,  A61K45/06 ,  G01N33/50

CPC分类号： C12N5/0676 ,  A61K9/1652 ,  A61K9/5036 ,  A61K35/39 ,  A61K35/545 ,  A61K45/06 ,  C12N2500/05 ,  C12N2500/22 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2500/90 ,  C12N2501/01 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/33 ,  C12N2501/335 ,  C12N2501/385 ,  C12N2501/395 ,  C12N2501/40 ,  C12N2501/727 ,  C12N2501/91 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/45 ,  G01N33/507

摘要： Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells.

公开(公告)号：US20170349876A1

公开(公告)日：2017-12-07

申请号：US15602899

申请日：2017-05-23

申请人： Corning Incorporated

发明人： Huayun Deng ,  Ye Fang ,  Qiang Fu ,  Aize Li ,  Lina Ma ,  John Christopher Mauro

IPC分类号： C12N5/00 ,  C03C3/064 ,  C12N5/071 ,  C03C3/19 ,  C03C4/00

CPC分类号： C12N5/0068 ,  C03C3/062 ,  C03C3/064 ,  C03C3/145 ,  C03C3/16 ,  C03C3/17 ,  C03C3/19 ,  C03C3/21 ,  C03C4/0007 ,  C03C4/0014 ,  C03C4/0035 ,  C12N5/069 ,  C12N2500/30 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/165 ,  C12N2501/30 ,  C12N2501/91 ,  C12N2533/12

摘要： A borophosphate glass composition including B2O3, P2O5, and CaO, and optionally a source additive selected from: Li2O, Na2O, K2O, Al2O3, ZnO, MgO, Fe2O3/FeO, CuO/Cu2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B2O3, P2O5, and CaO.

公开(公告)号：US20170226472A1

公开(公告)日：2017-08-10

申请号：US15501718

申请日：2015-08-04

申请人： Universidad de Granada ,  Universidad de Jaén ,  Servicio Andaluz de Salud

发明人： Juan Antonio Marchal Corrales ,  Gema Jiménez González ,  Cynthia Morata Tarifa ,  María Ángel García Chaves ,  Macarena Perán Quesada

IPC分类号： C12N5/00 ,  C12N5/095

CPC分类号： C12N5/0037 ,  C12N5/0695 ,  C12N2500/90 ,  C12N2501/10 ,  C12N2501/11 ,  C12N2501/113 ,  C12N2501/12 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2306 ,  C12N2501/2308 ,  C12N2501/2312 ,  C12N2501/2323 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2501/91 ,  C12N2501/999 ,  C12N2509/00

摘要： The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.

公开(公告)号：US20170151285A1

公开(公告)日：2017-06-01

申请号：US15429798

申请日：2017-02-10

申请人： Factor Bioscience Inc.

发明人： Matthew Angel ,  Christopher Rohde

IPC分类号： A61K35/28

CPC分类号： C12N5/0647 ,  A61K35/28 ,  A61K2035/124 ,  C08G77/08 ,  C08K5/5399 ,  C12N5/0657 ,  C12N9/16 ,  C12N9/22 ,  C12N15/87 ,  C12N15/907 ,  C12N2500/25 ,  C12N2500/44 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/26 ,  C12N2501/91 ,  C12N2501/998 ,  C12N2506/09 ,  C12N2800/80 ,  C12P21/00 ,  C12Y301/21 ,  H01L31/048 ,  Y02E10/50 ,  C08L83/04

摘要： The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

公开(公告)号：US09605278B2

公开(公告)日：2017-03-28

申请号：US15222453

申请日：2016-07-28

申请人： Factor Bioscience Inc.

发明人： Matthew Angel ,  Christopher Rohde

IPC分类号： C12N5/00 ,  C12N15/90 ,  C08K5/5399 ,  H01L31/048 ,  C12N15/87 ,  C12P21/00 ,  C12N9/16 ,  C12N5/0789 ,  C12N5/077 ,  C08G77/08

CPC分类号： C12N5/0647 ,  A61K35/28 ,  A61K2035/124 ,  C08G77/08 ,  C08K5/5399 ,  C12N5/0657 ,  C12N9/16 ,  C12N9/22 ,  C12N15/87 ,  C12N15/907 ,  C12N2500/25 ,  C12N2500/44 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/2303 ,  C12N2501/26 ,  C12N2501/91 ,  C12N2501/998 ,  C12N2506/09 ,  C12N2800/80 ,  C12P21/00 ,  C12Y301/21 ,  H01L31/048 ,  Y02E10/50 ,  C08L83/04

摘要： The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

公开(公告)号：US09567567B2

公开(公告)日：2017-02-14

申请号：US13816359

申请日：2011-08-11

申请人： Alexei Kirkin ,  Karine Djandjougazian ,  Martin Roland Jensen

发明人： Alexei Kirkin ,  Karine Djandjougazian ,  Martin Roland Jensen

IPC分类号： C12N5/0784 ,  C12N5/0783 ,  A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  A61K35/12

CPC分类号： C12N5/0639 ,  A61K35/15 ,  A61K35/17 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N5/0638 ,  C12N2500/90 ,  C12N2501/02 ,  C12N2501/2301 ,  C12N2501/2306 ,  C12N2501/25 ,  C12N2501/91 ,  C12N2506/115 ,  C12N2533/70 ,  C12N2533/90

摘要： The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells.

摘要翻译： 本发明涉及用于制备树突状细胞的组合物和方法，特别涉及用于产生免疫能力的未成熟树突状细胞的组合物和方法。 我们描述了通过培养单核细胞产生树突状细胞的方法，其特征在于以下至少之一：用至少一种以下的至少一种预处理组织培养表面：基本上无血浆和无血清的预处理培养基， 包含肝素的处理培养基和包含蛋白质溶液的预处理培养基; 使用基本上无血浆和无血清的吸附介质中的至少一种吸附单核细胞; 使用基本上无血浆和无血清的培养基培养单核细胞。 我们还描述了包括牙髓细胞和牙髓细胞的用途的组合物。

公开(公告)号：US09550974B2

公开(公告)日：2017-01-24

申请号：US14154163

申请日：2014-01-13

申请人： Advanced Cell Technology, Inc.

发明人： Robert P. Lanza ,  Young Gie Chung

IPC分类号： C12N5/00 ,  C12N5/0735 ,  C12N5/073 ,  C12N15/873

CPC分类号： C12N5/0606 ,  A61K35/545 ,  C12N5/0604 ,  C12N15/873 ,  C12N2501/119 ,  C12N2501/603 ,  C12N2501/91 ,  C12N2502/02 ,  C12N2506/02

摘要： This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.

摘要翻译： 本发明提供用于衍生胚胎干细胞，那些细胞和细胞系的新颖方法，以及用于治疗和研究目的而不破坏胚胎的细胞的用途。 它还涉及在植入胚胎之前建立和储存自体干细胞系的新方法，例如与生殖疗法如IVF结合。

公开(公告)号：US20170002322A1

公开(公告)日：2017-01-05

申请号：US15262515

申请日：2016-09-12

申请人： Anthrogenesis Corporation

发明人： Robert J. HARIRI ,  Mohammad A. HEIDARAN ,  Stephen JASKO ,  Lin KANG ,  Eric LAW ,  Ajai PAL ,  Bhavani STOUT ,  Vanessa VOSKINARIAN-BERSE ,  Andrew ZEITLIN ,  Xiaokui ZHANG

IPC分类号： C12N5/0783 ,  A61K35/17

CPC分类号： C12N5/0646 ,  A61K35/17 ,  A61K2035/124 ,  C12N2500/05 ,  C12N2500/25 ,  C12N2500/33 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2500/46 ,  C12N2500/84 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2302 ,  C12N2501/2303 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/26 ,  C12N2501/59 ,  C12N2501/91 ,  C12N2501/998 ,  C12N2506/11

摘要： Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

摘要翻译： 本文提供了使用两步膨胀和分化方法生产天然杀伤细胞的方法。 本文还提供了抑制肿瘤细胞增殖，治疗患有癌症或病毒感染的个体的方法，包括将通过该方法产生的NK细胞施用于具有癌症或病毒感染的个体。